DETECTION OF MICROMETASTATIC CANCER CELLS IN BLOOD & BONE MARROW - BREAST CANCER

血液中微转移癌细胞的检测

• 批准号: 7605787
• 负责人: DAVID N KRAG
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605787
• 关键词: Adjuvant Therapy; Blood; Bone Marrow; Breast; Breast Cancer Cell; Cancer Patient; Computer Retrieval of Information on Scientific Projects Database; Detection; Diagnostic Neoplasm Staging; Disease; Excision; Funding; Grant; Growth; Institution; Malignant Neoplasms; Methods; Operative Surgical Procedures; Other Agency or Organization; Outcome; Patients; Prevalence; Primary Neoplasm; Research; Research Personnel; Residual Cancers; Resources; Source; Staging; Testing; United States National Institutes of Health; base; cancer cell; improved; lymph nodes; malignant breast neoplasm; size

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The best chance for cure of breast cancer occurs when malignancies are detected and treated at the earliest possible stage and appropriate surgical and adjuvant therapies are administered. Developing a test which could effectively identify early stage cancers has the potential to greatly improve patient outcomes. Following surgical resection of the primary tumor, systemic adjuvant therapy is administered to eliminate growth of all breast cancer cells that have spread outside of the breast. Currently, an educated guess is made as to which patients are most likely to have residual cancer located outside the breast. This guess is based on the size of the primary tumor and whether cancer cells are present in lymph nodes around the breast. Developing a test that could better identify those patients harboring cancer cells in their body, but outside the breast, has the potential to improve patient outcomes. The objectives of this study are to 1) Determine the efficacy of the methods for detecting cancer cells in the blood and bone marrow, 2) Assess the sensitivity of each method, and 3) Estimate the prevalence of cancer cells in the blood and bone marrow of breast cancer patients at different stages of the disease.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 当尽早发现并治疗恶性肿瘤并进行适当的手术和辅助治疗时，治愈乳腺癌的最佳机会就会出现。 开发一种可以有效识别早期癌症的测试有可能大大改善患者的治疗结果。 手术切除原发肿瘤后，进行全身辅助治疗，以消除所有已扩散到乳腺外的乳腺癌细胞的生长。 目前，人们对哪些患者最有可能在乳房外有残留癌症做出了有根据的猜测。 这一猜测是基于原发肿瘤的大小以及乳房周围淋巴结中是否存在癌细胞。 开发一种测试可以更好地识别那些体内携带癌细胞但在乳房外的患者，有可能改善患者的治疗结果。 本研究的目的是 1) 确定检测血液和骨髓中癌细胞的方法的有效性，2) 评估每种方法的敏感性，以及 3) 估计乳腺癌患者在疾病不同阶段的血液和骨髓中癌细胞的患病率。